Life to Science BIOMM. Institutional Presentation. October 2016

Transcription

1 Life to Science BIOMM Institutional Presentation October

2 DISCLAIMER This presentation and its contents are confidential and proprietary Biomm SA and its subsidiaries ( "Biomm"). By accepting this presentation, each recipient agree that you will not copy, reproduce or distribute to third parties the content of this presentation in whole or in part, without the prior written consent of Biomm. Except as otherwise provided herein, this presentation contains information and opinions which refer only to the date hereof and are subject to change without notice. The content of this presentation does not constitute a promise or representation regarding the future performance of the Company. Certain information and conclusions contained herein are based on projections, which Biomm believed to be reasonable, but have not been independently verified. Several factors could cause future results, performance or Biomm s events to be substantially different from those described in this presentation. Biomm, its directors, officers and employees shall not, under any circumstances, be liable to third parties (including investors) for investment decisions or acts or business carried out based on the information and statements contained in this presentation, or for indirect damage or profit loss. This presentation and its contents do not constitute basis for any contract or commitment whatsoever. This presentation has been prepared for informational purposes only and should not be interpreted otherwise. 2

3 BIOMM HAS STRONG TIES WITH INSULIN PRODUCTION IN BRAZIL Establishment of Biobrás: Enzyme production using both animal and vegetable raw materials Joint venture with North American Eli Lilly & Co: Production of insulin of animal origin in Brazil Biobrás buys Eli Lilly s share in the Joint Venture: Manufacture of highly purified insulin First production patent for recombinant human insulin Establishment of Biomm: Intellectual property, knowhow, researchers and executives remain the same 3

4 WHAT MAKES BIOMM THE BEST PARTNER IN BIOPHARMACEUTICALS IN BRAZIL? 4

5 Private Strategic and Government funds Experienced, specialized professionals Organization Structure BIOMM IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL Industrial plant already under construction Know-how, technology and patents in key global markets 5

6 First class team Executives with extensive experience and expertise are leading BIOMM: GUILHERME EMRICH HERALDO MARCHEZINI LUCIANO VILELA FRANCISCO FREITAS DOUGLAS LOPES CIRO MASSARI Chairman of the Board CEO Technology Director Operations Director CFO & IR Commercial Director Internationally recognized biotech entrepreneur 25 years of experience in the industry, former Sanofi s CEO in Brazil Expert in the R&D field; author of several BIOMM s patents 30+ years of experience; responsible for the plant project 5+ years experience in Management Consulting industry COO / Marketing Director 20+ of experience in the sector Sales and Marketing Director at Sanofi Brasil and Mexico 6

7 Organization Structure Supporting team covering most important areas in biotech project implementation: CEO BUSINESS DEVELOP. HR COO CTO CFO COMMERCIAL DIRECTOR MAINTENAN- CE AND PROCESSES ENGINEERING R&D REGULATORY CONTROLLER TREASURY MARKETING SALES CONSTRUCTI ON MGMT OSHA QUALITY ASSURANCE QUALITY CONTROL ACCOUNTING LEGAL MEDICAL MANAGER 7

8 Innovation Track Record The company preserved the intellectual capital, know-how and R&D team that made Biobrás an outstanding case of success. An old relation with insulin in both production and technology development, and a number of patents granted in demanding countries like USA, Germany and Israel 8

9 Over 20patents in key global markets 9

10 Structure Minas Gerais: Belo Horizonte: Administrative office Contagem: Distribution Center Montes Claros: R&D Lab Nova Lima: Industrial Plant São Paulo: São Paulo: Commercial office A modern m 2 biopharmaceutical plant is already being built in Nova Lima, MG and will be completed in

11 Has positioned itself to the next wave of biologics Pernambuco: Recife: Biologics Plant Recently acquired real state area from Novartis for future portfolio expansion in biologics 11

12 Funding The only Biopharmaceutical company listed in the BOVESPA stock exchange (BIOM3) Innovation Capital, by both private and public funds 12

13 Funding Solid capital structure that allow multiple sources of additional resources Founding Partners 27,7% Minority and Float 23,3% Equity Distribution 5,2% 8,1% 14,0% 21,7% Private Equity 13

14 Private Strategic and Government funds Experienced, specialized professionals Organization Structure BIOMM IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL Industrial plant already under construction Know-how, technology and patents in key global markets 14

15 A SOLID REALITY A solid company, led by skilled professionals and investing heavily in one of the world s most important industries 15